Extensive Stage Small Cell Lung CancerPhase 2DeLLphi-307NCT06502977

Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

A Phase 2 study testing Tarlatamab in people with Extensive Stage Small Cell Lung Cancer, run by Amgen at 12 sites in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Extensive Stage Small Cell Lung Cancer
What is being tested?: Tarlatamab
Type of treatment: Injection or infusion
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 32 participants
Where: 12 sitesChina
Study dates: 27 Aug 2024to 10 Dec 2027
Phase: Phase 2
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Participant has provided informed consent prior to initiation of any study specific activities/procedures.
Participant must be a resident in China, and of Chinese ancestry ≥ 18 years of age (or legal adult age within country) at the time of signing the informed consent.
Histologically or cytologically confirmed small cell lung cancer.
Extensive-stage SCLC participants who progressed on or recurred following 1 platinum-based regimen as 1L therapy (including a PD-1/PD-[L]1) and at least 1 other prior line of therapy.
Measurable lesions as defined per RECIST 1.1 within 21 days prior to the first dose of study drug.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Minimum life expectancy of 12 weeks.
Adequate organ function.

Who cannot join

Disease Related
Any previous diagnosis of transformed non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC.
Symptomatic central nervous system (CNS) metastases.
Diagnosis or evidence of leptomeningeal disease.
Prior history of severe or life-threatening events from any immune-mediated therapy.
Other Medical Conditions

Show all 33Show fewer

Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study.
History of solid organ transplantation.
Evidence of interstitial lung disease or active, non-infectious pneumonitis.
History of other malignancy within the past 2 years, with certain exceptions
Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association > class II) within 12 months of first dose of study drug.
History of arterial thrombosis (eg, stroke or transient ischemic attack) within 12 months of first dose of study drug.
Participants with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study drug.
HIV, Hepatitis B, and Hepatitis C, with certain exceptions.
Major surgery within 28 days of first dose study drug. Prior/Concomitant Therapy
Currently or previously enrolled in a tarlatamab study.
Prior therapy with any selective inhibitor of the DLL3 pathway.
Prior anti-cancer therapy within 21 days prior to first dose of study treatment, with certain exceptions.
Receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug, with certain exceptions.
Treatment with live virus, including live-attenuated vaccination, within 14 days prior to the first dose of study drug. Inactive vaccines (eg, non-live or non-replicating agent) and live viral non-replicating vaccines (eg, Jynneos for mpox infection) within 3 days prior to first dose of study drug.
Prior/Concurrent Clinical Study Experience
Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
Other Exclusions
Female participants of childbearing potential unwilling to use protocol-specified method of contraception during treatment and for an additional period of time after the last dose of study drug as specified in the study protocol.
Female participants who are breastfeeding or who plan to breastfeed while on study and for an additional period of time after the last dose of study drug as specified in the study protocol.
Female participants planning to become pregnant or donate eggs while on study and for an additional period of time after the last dose of study drug as specified in the study protocol.
Female participants of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.
Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional period of time after the last dose of study drug as specified in the study protocol.
Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional period of time after the last dose of study drug as specified in the study protocol.
Male participants unwilling to abstain from donating sperm during treatment and for an additional period of time after the last dose of study drug as specified in the study protocol.
Participants has known sensitivity to any of the products or components to be administered during dosing.
Participants likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures.
History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or medical monitor if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.

Trial locations and contacts

12 sites in 1 country.

City, postcode or hospital

12 sites in 1 country

China12 sites

Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142
The Second Affiliated Hospital of Army Medical University, People's Liberation Army
Chongqing, Chongqing Municipality, 400037
Army Special Medical Center of Peoples Liberation Army
Chongqing, Chongqing Municipality, 400042
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, 350025
Fujian Cancer Hospital
Fuzhou, 350011
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, 510060
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009
Harbin Meidical University Cancer Hospital
Harbin, Heilongjiang, 150000
Jiangmen Central Hospital
Jiangmen, Guangdong, 529000
Taizhou Hospital of Zhejiang Province
Linhai, Zhejiang, 317000
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430030

Other trials in China

About this study

Official title: Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)

Conditions: Extensive Stage Small Cell Lung Cancer
Being tested: Tarlatamab
Keywords: Extensive Stage Small Cell Lung Cancer, Advanced Small Cell Lung Cancer, SCLC, AMG 757, Tarlatamab, IMDELLTRA, Tumor, Programmed Cell Death Protein 1, Programmed Cell Death Ligand 1, PD-1 Protein, PD-L1 Protein, Pharmacokinetics, Malignancy, Cancer, Chinese Participants, China, Platinum, Platinum-based, Neuroendocrine tumor, Bi-specific T-cell engager
Medical subject headings: Neoplasms, Neuroendocrine Tumors

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

TarlatamabDrug
Also called AMG 757, IMDELLTRA™
IV infusion

Study groups in NCT06502977
Study group	Role	What they receive
Tarlatamab	Experimental	Participants will receive tarlatamab as an intravenous (IV) infusions in 28-day cycles. Receives: Drug: Tarlatamab

What is being measured

The primary outcome is the main question the study is designed to answer.

Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
ORR based on BICR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) plus partial response (PR).
CR: Disappearance of all target non-nodal lesions. Any target lymph node must have had a reduction in short axis to <10 mm, NOT total disappearance.
PR: At least a 30% decrease in the sum of the diameters of target lesions, taken as reference the baseline sum of diameters. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 is presented.
Measured: From first dose of trial drug up to a minimum of last dose + 65 days or data cutoff date; median (min, max) time on trial was 3.4 (2.2, 6.5) months at data cut off

Secondary outcomes (13)

Duration of Response (DOR) Based on BICR Per RECIST 1.1
DOR was defined as time from the first documentation of OR until the first documentation of disease progression (PD) or death due to any cause, whichever occured first. Only participants who had achieved OR were evaluated for DOR. CR: Disappearance of all target non-nodal lesions. Any target lymph node must have reduction in short axis to <10 mm, NOT total disappearance. PD: At least 20% increase in the sum of the diameters of target lesions, taken as reference smallest sum on trial (this included the baseline sum if that is the smallest on trial). In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. If a participant was missing lesion data at a disease assessment and yet progressive disease criteria was met despite the missing data, the participant would be classified as having PD.
Measured: Approximately 24 months
Disease Control (DC) Based on BICR Per RECIST 1.1
DC was defined as CR + PR + stable disease (SD). CR: Disappearance of all target non-nodal lesions. Any target lymph node must have had a reduction in short axis to <10 mm, NOT total disappearance. PR: At least a 30% decrease in the sum of the diameters of target lesions, taken as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least 20% increase in the sum of the diameters of target lesions, taken as reference smallest sum on trial (this included the baseline sum if that is the smallest on trial). In addition to the relative increase of 20%, the sum must have also demonstrate an absolute increase of at least 5 mm. If a participant was missing lesion data at a disease assessment and yet progressive disease criteria was met despite the missing data, the participant would be classified as having PD.
Measured: Approximately 24 months
Duration of DC Based on BICR Per RECIST 1.1
Duration of DC was defined as time from first documentation of CR,PR, or SD until first documentation of disease progression or death due to any cause, whichever occurred first. Only participants who had achieved CR,PR, or SD would be evaluated for Duration of DC. CR:Disappearance of all target non-nodal lesions.Any target lymph node must have reduction in short axis to <10 mm,NOT total disappearance.PR:At least a 30% decrease in sum of diameters of target lesions, taken as reference baseline sum of diameters. SD:Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD:At least 20% increase in sum of diameters of target lesions, taken as reference smallest sum on trial.In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 mm.If participant was missing lesion data at disease assessment and yet progressive disease criteria was met despite missing data, participant would be classified as having PD.
Measured: Approximately 24 months
Progression-free Survival (PFS) Based on BICR Per RECIST 1.1
PFS was defined as the time from first dose of tarlatamab until PD or death from any cause, whichever occurred first. At least a 20% increase in the sum of the diameters of target lesions, taken as reference the smallest sum on trial (this included the baseline sum if that was the smallest on trial). In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. If a participant was missing lesion data at a disease assessment and yet progressive disease criteria was met despite the missing data, the participant would be classified as having PD.
Measured: Approximately 24 months
ORR Based on Investigator Assessment Per RECIST 1.1
ORR based on investigator assessment was defined as the percentage of participants with BOR of CR plus PR. CR: Disappearance of all target non-nodal lesions. Any target lymph node must have had a reduction in short axis to <10 mm, NOT total disappearance. PR: At least a 30% decrease in the sum of the diameters of target lesions, taken as reference the baseline sum of diameters.
Measured: Approximately 24 months
DOR Based on Investigator Assessment Per RECIST 1.1
DOR was defined as time from the first documentation of OR until the first documentation of PD or death due to any cause, whichever occurred first. Only participants who had achieved OR would be evaluated for DOR. PD: At least 20% increase in the sum of the diameters of target lesions, taken as reference smallest sum on trial (this included the baseline sum if that was the smallest on trial). In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. If a participant was missing lesion data at a disease assessment and yet progressive disease criteria was met despite the missing data, the participant would be classified as having PD.
Measured: Approximately 24 months
DC Based on Investigator Assessment Per RECIST 1.1
DC was defined as CR + PR + SD. CR: Disappearance of all target non-nodal lesions. Any target lymph node must have had a reduction in short axis to <10 mm, NOT total disappearance. PR: At least a 30% decrease in the sum of the diameters of target lesions, taken as reference the baseline sum of diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD: At least 20% increase in the sum of the diameters of target lesions, taken as reference smallest sum on trial (this included the baseline sum if that was the smallest on trial). In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. If a participant was missing lesion data at a disease assessment and yet progressive disease criteria was met despite the missing data, the participant would be classified as having PD.
Measured: Approximately 24 months
Duration of DC Based on Investigator Assessment Per RECIST 1.1
Duration of DC was defined as time from first documentation of CR,PR, or SD until first documentation of disease progression or death due to any cause, whichever occurred first. Only participants who had achieved CR,PR, or SD would be evaluated for Duration of DC. CR:Disappearance of all target non-nodal lesions.Any target lymph node must have reduction in short axis to <10 mm,NOT total disappearance.PR:At least a 30% decrease in sum of diameters of target lesions, taken as reference baseline sum of diameters. SD:Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD:At least 20% increase in sum of diameters of target lesions, taken as reference smallest sum on trial.In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 mm.If participant was missing lesion data at disease assessment and yet progressive disease criteria was met despite missing data, participant would be classified as having PD.
Measured: Approximately24 months
PFS Based on Investigator Assessment Per RECIST 1.1
PFS was defined as time from enrollment until PD or death from any cause, whichever occurred first. At least a 20% increase in the sum of the diameters of target lesions, taken as reference the smallest sum on trial (this included the baseline sum if that was the smallest on trial). In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. If a participant was missing lesion data at a disease assessment and yet progressive disease criteria was met despite the missing data, the participant would be classified as having PD.
Measured: Approximately 24 months
Overall Survival (OS)
OS was defined as time from the first dose of tarlatamab until death from any cause.
Measured: Approximately 24 months
Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a clinical trial participant irrespective of a causal relationship with the trial treatment. TEAEs were defined as AEs starting on or after the first dose of tarlatamab up to the safety follow-up (SFU) visit or 60 days after the last dose of tarlatamab, whichever was later.
Measured: Approximately 24 months
Trough Concentration (Ctrough) of Tarlatamab
Ctrough of tarlatamab was calculated using standard noncompartmental methods.
Measured: Approximately 24 months
Number of Participants With Anti-tarlatamab Antibodies Formation
Number of participants with anti-tarlatamab (binding and neutralizing) antibodies was presented.
Measured: Approximately 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

27 Aug 202410 Dec 2027

First posted16 Jul 2024
Study start27 Aug 2024
Primary completion28 Mar 2025
Study completion10 Dec 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Extensive Stage Small Cell Lung CancerStudies of the same condition, open and under way.
More trials run by AmgenThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 32 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06502977
Sponsor's protocol ID: 20230273
Acronym: DeLLphi-307
Status last verified: Sep 2026
First submitted: 9 Jul 2024
Last updated: 21 Oct 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer
Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
RecruitingPhase 2
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
Small-cell Lung Cancer
Not yet recruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer
Extensive Stage-Small Cell Lung Cancer
Active, not recruitingPhase 2
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer
Not yet recruitingPhase 1
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
Extensive Stage Small Cell Lung Cancer (ES-SCLC)

All Extensive Stage Small Cell Lung Cancer trials

Study at a glance

From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Phase 2a Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of Tarlatamab in Chinese Subjects With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-307)
ClinicalTrials.gov ID: NCT06502977
Acronym / sponsor ID: DeLLphi-307 / 20230273
Conditions: Extensive Stage Small Cell Lung Cancer
Keywords: Extensive Stage Small Cell Lung Cancer, Advanced Small Cell Lung Cancer, SCLC, AMG 757, Tarlatamab, IMDELLTRA, Tumor, Programmed Cell Death Protein 1
Phase: Phase 2
Study type: Interventional
Recruitment status: Active, not recruiting
Enrolment: 32 participants (actual)
Lead sponsor: AmgenIndustry (pharma, biotech, devices)
Study start: 27 Aug 2024 (actual)
Primary completion: 28 Mar 2025 (actual)
Study completion: 10 Dec 2027 (estimated)
First posted: 16 Jul 2024 (actual)
Results: Posted 15 Apr 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1

Arm	Type	Receives
Tarlatamab	Experimental	Drug: TarlatamabParticipants will receive tarlatamab as an intravenous (IV) infusions in 28-day cycles.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (8 listed)

Participant has provided informed consent prior to initiation of any study specific activities/procedures.
Participant must be a resident in China, and of Chinese ancestry ≥ 18 years of age (or legal adult age within country) at the time of signing the informed consent.
Histologically or cytologically confirmed small cell lung cancer.
Extensive-stage SCLC participants who progressed on or recurred following 1 platinum-based regimen as 1L therapy (including a PD-1/PD-[L]1) and at least 1 other prior line of therapy.
Measurable lesions as defined per RECIST 1.1 within 21 days prior to the first dose of study drug.

Key exclusion criteria (33 listed)

Disease Related
Any previous diagnosis of transformed non-small cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) activating mutation positive NSCLC that has transformed to SCLC.
Symptomatic central nervous system (CNS) metastases.
Diagnosis or evidence of leptomeningeal disease.
Prior history of severe or life-threatening events from any immune-mediated therapy.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
TarlatamabAlso: AMG 757, IMDELLTRA™IV infusion	Drug	Tarlatamab

Primary outcome

Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Time frame: From first dose of trial drug up to a minimum of last dose + 65 days or data cutoff date; median (min, max) time on trial was 3.4 (2.2, 6.5) months at data cut off
ORR based on BICR was defined as the percentage of participants with best overall response (BOR) of complete response (CR) plus partial response (PR). CR: Disappearance of all target non-nodal lesions. Any target lymph node must have had a reduction in short axis to <10 mm, NOT total disappearance. PR: At least a 30% decrease in the sum of the diameters of target lesions, taken as reference the baseline sum of diameters. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 is presented.

13 secondary outcomes

Duration of Response (DOR) Based on BICR Per RECIST 1.1
Time frame: Approximately 24 months
Disease Control (DC) Based on BICR Per RECIST 1.1
Time frame: Approximately 24 months
Duration of DC Based on BICR Per RECIST 1.1
Time frame: Approximately 24 months
Progression-free Survival (PFS) Based on BICR Per RECIST 1.1
Time frame: Approximately 24 months
ORR Based on Investigator Assessment Per RECIST 1.1
Time frame: Approximately 24 months
DOR Based on Investigator Assessment Per RECIST 1.1
Time frame: Approximately 24 months
DC Based on Investigator Assessment Per RECIST 1.1
Time frame: Approximately 24 months
Duration of DC Based on Investigator Assessment Per RECIST 1.1
Time frame: Approximately24 months
PFS Based on Investigator Assessment Per RECIST 1.1
Time frame: Approximately 24 months
Overall Survival (OS)
Time frame: Approximately 24 months
Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)
Time frame: Approximately 24 months
Trough Concentration (Ctrough) of Tarlatamab
Time frame: Approximately 24 months
Number of Participants With Anti-tarlatamab Antibodies Formation
Time frame: Approximately 24 months

Results and safety

Results posted to the registry on 15 Apr 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Tarlatamab	32	0

Primary outcome: Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

Time frame: From first dose of trial drug up to a minimum of last dose + 65 days or data cutoff date; median (min, max) time on trial was 3.4 (2.2, 6.5) months at data cut off. Number (95% Confidence Interval). Unit: percentage of participants

Measure	Tarlatamab n = 31
Value	38.7 (21.8 to 57.8)

Population analysed: The safety analysis set consisted of all participants who received at least 1 dose of tarlatamab.

13 secondary outcomes are reported in the full results.

Adverse events

Time frame: For all-cause mortality, from enrollment until death or data cut-off: Median (min, max) was 3.8 (0.7, 7.0) months; AEs were collected from first dose of tarlatamab until last dose + 65 days or data cut-off: Median (min, max) duration was 3.4 (2.2, 6.5) months. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Tarlatamab	7 of 31 (22.6%)	31 of 31 (100%)	3 of 32

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
AmgenTrials clinical trials websiteLink provided by the sponsor.
Individual participant dataSharing planned: Yes. De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Related trials for Extensive Stage Small Cell Lung Cancer

Not yet recruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer
Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
RecruitingPhase 2
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
Small-cell Lung Cancer
Not yet recruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer
Extensive Stage-Small Cell Lung Cancer
Active, not recruitingPhase 2
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer
Not yet recruitingPhase 1
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

MD study director

Amgen

12 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Tarlatamab in people with Extensive Stage Small Cell Lung Cancer, run by Amgen at 12 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 33 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Apr 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (time frame: From first dose of trial drug up to a minimum of last dose + 65 days or data cutoff date; median (min, max) time on trial was 3.4 (2.2, 6.5) months at data cut off). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06502977.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.